A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Hosted on MSN17h
Lilly forecasts weak sales of weight-loss drug in fourth quarter(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall ...
A major insurance company is no longer covering drugs like Zepbound prescribed solely for weight loss blaming exorbitant ...
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
For those looking to attain a healthy body weight in 2025, there are a few options to consider. Dr. Will Cauthen, a board-certified surgeon at the Surgery Clinic of Tupelo who specializes in abdominal ...
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback